Navigation Links
Study Examines Smart Pharma Strategies for Effective Messaging around New Products and the Medical Conditions they Treat
Date:10/28/2012

CHAPEL HILL, NC, Oct. 28, 2012 /PRNewswire/ -- According to recent research, more than 50% of leading pharma companies expect social networking, online video, and other types of Digital Marketing to grow in use as critical tools for communicating disease state and product information.

New pharmaceutical products - particularly those that are first-in-class - require not only external disease state communication but also internal communication to win support in the marketplace. 

Now, a critical Best Practices, LLC benchmarking report, "Raising Disease State Awareness: Best Practices in Internal Brand Messaging for New Products," examines how companies communicate at the brand and disease state levels in order to educate employees internally and create a consistent, credible external message surrounding new products.

The study spells out 10 key best practices culled from in-depth interviews with benchmark participants, who were involved in pre-launch, internal communication for Viagra, Gardasil, Prozac and many other successful brands.

Comprising in-depth surveys and interviews with 32 top biopharma companies, this report enables marketing and brand team leaders to implement the type of well-timed and well-targeted internal communications strategies essential for cementing both the medical and commercial framework for a new product's market entry and supporting its overall success as a brand.

Key topic areas analyzed in this study include:

  • Effective communication channels & use of new communication technologies
  • Timing of communication activities by product development phase
  • Advantages & disadvantages of employee message segmentation
  • Tracking internal message effectiveness
  • Preventing sensitive-information leaks
  • Using KOLs to influence employees
  • Needs creation marketing tactics

For a free summary of this 67-page report, go to: http://www.best-in-class.com/rr1183.htm.

For more information on this study and other recent primary research studies, contact us at 919.403.0251 or at bestpractices@best-in-class.com.

BEST PRACTICES, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies.

The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations.

Best Practices, LLC believes in the profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies.

 


'/>"/>
SOURCE Best Practices, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Onboarding Programs are Opportunity for Organizations to Plant the Seeds of Employee Engagement and Retention
2. CORRECTION: Star Scientific Issues Statement Correcting the Underreporting of the "Flint" CRP Human Study Results
3. ADVENTRX Announces Details Of The Phase 3 Study Of ANX-188
4. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
5. Imprimis to Begin New Study of Its Topical Analgesic Drug
6. NKTR-192, A New Short-Acting Mu-Opioid Analgesic Molecule, Achieves Desired Pharmacokinetic Profile in First Phase 1a Clinical Study
7. Study Published In Contraception Evaluates Medical Expenditures For Unintended Pregnancies And Potential Cost Impact Of Increased Use Of Long-Acting Reversible Contraception
8. Pearl Therapeutics Completes Phase 2b Study of Glycopyrrolate, Defines Dose-Response Curve and Identifies Optimal Dose of PT001
9. BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone
10. Study Results of Artificial Disc Recipients Show Significant Improvement Compared to Pre-Surgery Condition
11. IncellDx, Inc. Announces an Agreement with BioReference Laboratories, Inc. to Conduct a 10,000 Sample Study Using a Slideless Pap Smear
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... PARSIPPANY, N.J. , Dec. 5, ... Sankyo) today announced preliminary safety and efficacy data ... investigational oral selective MDM2 inhibitor, suggesting that DS-3032 ... including relapsed/refractory acute myeloid leukemia (AML) and high-risk ... escalation part of the phase 1 study of DS-3032 ...
(Date:12/5/2016)... -- BD (Becton, Dickinson and Company) (NYSE: BDX ... an enhanced technology platform designed with the ability to ... Pyxis™ and Alaris™ systems, at this year,s American ... being held in Las Vegas ... that approximately 68 percent of medication errors occur during ...
(Date:12/5/2016)... Eisai Inc. announced today new analyses and ... of the American Epilepsy Society (AES). ... adjunctive therapy for the treatment of partial onset seizures ... generalized tonic-clonic seizures (PGTC) in patients with epilepsy who ... Important Safety Information for FYCOMPA, including Boxed WARNING for ...
Breaking Medicine Technology:
(Date:12/6/2016)... ... 06, 2016 , ... The NALA, a boutique marketing agency, is proud to ... (TBCF), a nonprofit 501(C)(3) organization providing financial and emotional support to families of children ... TBCF, the NALA recently hosted a Thanksgiving food drive that resulted in four boxes ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... proud to announce it has added CXC Solutions (CXC) as a new Strategic ... These solutions are tailored to help benefits advisors reduce operating costs and generate ...
(Date:12/6/2016)... ... 06, 2016 , ... Just in time for the holiday season, the celebrated ... recipe for Honeyville’s new Organic Quinoa Flour product for sale at Costco stores throughout ... future. , “I think it’s wonderful that a growing number of retailers such ...
(Date:12/6/2016)... CA (PRWEB) , ... December 06, 2016 , ... 'Tis ... can disrupt daily routines. That means it's also the season when eating healthy, staying ... living with diabetes) on schedule is harder to do. , "Shopping trips, parties ...
(Date:12/6/2016)... ... 06, 2016 , ... TopConsumerReviews.com recently gave a best-in-class 5 star rating to ... give freedom to people who need help getting around. For some, advancing age has ... period of rehabilitation after an illness or accident. There is a wide variety of ...
Breaking Medicine News(10 mins):